Secondary Hyperparathyroidism - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 69 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Secondary Hyperparathyroidism - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Secondary Hyperparathyroidism - Pipeline Review, H1 2015', provides an overview of the Secondary Hyperparathyroidism's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Secondary Hyperparathyroidism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Secondary Hyperparathyroidism and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Secondary Hyperparathyroidism
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Secondary Hyperparathyroidism and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Secondary Hyperparathyroidism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Secondary Hyperparathyroidism pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Secondary Hyperparathyroidism
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Secondary Hyperparathyroidism Overview 7
Therapeutics Development 8
Pipeline Products for Secondary Hyperparathyroidism - Overview 8
Pipeline Products for Secondary Hyperparathyroidism - Comparative Analysis 9
Secondary Hyperparathyroidism - Therapeutics under Development by Companies 10
Secondary Hyperparathyroidism - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Secondary Hyperparathyroidism - Products under Development by Companies 14
Secondary Hyperparathyroidism - Companies Involved in Therapeutics Development 15
Amgen Inc. 15
Astellas Pharma Inc. 16
Deltanoid Pharmaceuticals Inc. 17
Mitsubishi Tanabe Pharma Corporation 18
NPS Pharmaceuticals, Inc. 19
OPKO Health, Inc. 20
Secondary Hyperparathyroidism - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
ASP-7991 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
calcifediol - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Calcimimetic-18 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
CARD-024 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
cinacalcet hydrochloride - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
CTA-091 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
CTAP-201 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
DP-001 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
lunacalcipol - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
MT-4580 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
velcalcetide - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
VS-105 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
VS-110 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
VS-411 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Secondary Hyperparathyroidism - Recent Pipeline Updates 50
Secondary Hyperparathyroidism - Dormant Projects 59
Secondary Hyperparathyroidism - Product Development Milestones 60
Featured News & Press Releases 60
Oct 15, 2014: Deltanoid's DP001 (2MD) pharmaceutical demonstrated safe and effective in kidney failure patients on dialysis 60
Sep 23, 2014: OPKO's Second Rayaldee Phase 3 Trial Meets Primary Endpoints 60
Aug 29, 2014: Kyowa Hakko Kirin Announces Commencement of Phase 2b Clinical Study of KHK7580 in Patients with Secondary Hyperparathyroidism in Japan 62
Aug 18, 2014: Amgen Announces Positive Top-Line Results From Second Phase 3 Study Of AMG 416 For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Receiving Hemodialysis 62
Aug 11, 2014: Rayaldee Phase 3 Trial Meets Primary Endpoints 63
Aug 07, 2014: OPKO Submits IND for Rayaldee as Adjunctive Cancer Therapy 64
Jul 22, 2014: OPKO Granted Patent from US Patent & Trademark Office for RAYALDEE 65
Dec 19, 2013: OPKO Completes Patient Recruitment in Second Phase 3 Trial of Rayaldy 65
Aug 15, 2013: OPKO Surpasses 50% Enrollment in Second Phase 3 Trial of Rayaldy 66
Jun 27, 2013: Kyowa Hakko Kirin Files Application Seeking Approval For Additional Indication For Regpara Tablets 25mg And 75mg 67
Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 69
Disclaimer 69

List of Tables
Number of Products under Development for Secondary Hyperparathyroidism, H1 2015 8
Number of Products under Development for Secondary Hyperparathyroidism - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Secondary Hyperparathyroidism - Pipeline by Amgen Inc., H1 2015 15
Secondary Hyperparathyroidism - Pipeline by Astellas Pharma Inc., H1 2015 16
Secondary Hyperparathyroidism - Pipeline by Deltanoid Pharmaceuticals Inc., H1 2015 17
Secondary Hyperparathyroidism - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 18
Secondary Hyperparathyroidism - Pipeline by NPS Pharmaceuticals, Inc., H1 2015 19
Secondary Hyperparathyroidism - Pipeline by OPKO Health, Inc., H1 2015 20
Assessment by Monotherapy Products, H1 2015 21
Number of Products by Stage and Target, H1 2015 23
Number of Products by Stage and Mechanism of Action, H1 2015 25
Number of Products by Stage and Route of Administration, H1 2015 27
Number of Products by Stage and Molecule Type, H1 2015 29
Secondary Hyperparathyroidism Therapeutics - Recent Pipeline Updates, H1 2015 50
Secondary Hyperparathyroidism - Dormant Projects, H1 2015 59